UBS Oconnor LLC
- SEC CIK
- 0001132716
- Latest filing
- Aug 14, 2026
ACRV holding history
Acrivon Therapeutics, Inc. in every 13F filed by UBS Oconnor LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ACRV overviewAll 13F holders of ACRVFull Q4 2025 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 8
- Since Q2 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −15,576−100.0% | Sold out | Holders |
| Q1 2025 | 15,576 | $31.6K | <0.1% | −87,208−84.8% | Reduced | Holders |
| Q4 2024 | 102,784 | $618.8K | <0.1% | +23,535+29.7% | Added | Holders |
| Q3 2024 | 79,249 | $554.7K | <0.1% | −26,000−24.7% | Reduced | Holders |
| Q2 2024 | 105,249 | $610.4K | <0.1% | −21,700−17.1% | Reduced | Holders |
| Q1 2024 | 126,949 | $907.7K | <0.1% | +33,506+35.9% | Added | Holders |
| Q4 2023 | 93,443 | $459.7K | <0.1% | −11,557−11.0% | Reduced | Holders |
| Q3 2023 | 105,000 | $1.00M | <0.1% | +5,000+5.0% | Added | Holders |
| Q2 2023 | 100,000 | $1.30M | <0.1% | +100,000 | New | Holders |